Abbott Laboratories Stock Draws Fresh Targets As Growth Story Builds

Abbott Laboratories gains momentum as pivotal medical device approvals fuel optimism, and stocks have been trading up by 10.66 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ABT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Baird initiated coverage of Abbott Laboratories with an Outperform rating and a $121 price target, citing 6%-8% annual sales growth, low double-digit earnings growth, and upside from new products and Exact Sciences synergies.
Citi’s sum-of-the-parts valuation suggests Abbott shares could be worth $99-$104 versus the current $89, as easing headwinds and a new product cycle underpin its reiterated Buy rating.
Abbott signed a global licensing agreement with ALZpath to use its clinically validated pTau217 antibody to develop a blood-based in vitro diagnostic test for Alzheimer’s disease on its widely installed Alinity ci-series instruments.
The U.S. Department of Justice closed its years-long investigation into Abbott’s baby formula operations without filing criminal charges, instead pursuing a civil False Claims Act settlement focused on recovering federal nutrition-program funds.
Evercore ISI cut its Abbott price target to $112 from $120 but maintained an Outperform rating, pointing to generally healthy procedure volumes and capital expenditure trends in MedTech, life sciences tools, and diagnostics ahead of Q2.

Live Update At 16:02:21 EDT: On Thursday, July 16, 2026 Abbott Laboratories stock [NYSE: ABT] is trending up by 10.66%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ABT has quietly switched from grind mode to breakout mode on the chart. Over the past few weeks, Abbott Laboratories climbed from the high-$80s to close at $98.81 on 2026/07/16, after briefly tagging $101.87 intraday. That’s a strong squeeze off the 2026/06/22 low near $87.83, with higher lows stacking almost every few sessions.

Intraday, ABT trading showed tight, controlled action. Most 5‑minute candles lived between $98 and $100, with buyers defending dips toward $98 and sellers showing up just over $100. For short-term traders, that sets a clear battlefield: $100-$101 as near resistance, mid-$98s as intraday support.

More Breaking News

Under the hood, Abbott Laboratories is not a story stock; it’s a cash machine. Trailing revenue runs near $44.3B with gross margin of 56.3% and EBIT margin around 19.2%. Return on equity above 18% and a price/earnings ratio near 25.4 put ABT in the quality-growth bucket, not the bargain bin. Debt looks manageable, with total debt-to-equity at 0.65 and interest coverage over 22 times. For traders, that balance sheet stability often means pullbacks are driven more by headlines than survival risk.

Why Traders Are Watching ABT Now

The real action in ABT is in the narrative. Several big Wall Street desks are lining up on the bullish side, and that matters for medium-term trading flows.

Baird just initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, above the already-strong Street average near $115.74. The thesis is clear: 6%-8% annual sales growth, low double-digit earnings growth, and upside from new products plus synergies with Exact Sciences into 2027-2028. For traders, that long runway tells you funds can justify buying dips for years, not days.

Citi backs that optimism with a sum-of-the-parts view that pegs ABT at $99-$104 versus a prior $89 spot price. The key phrase is “easing headwinds” and “new product cycle.” That fits what we’re seeing in the tape: a breakout above the $90-$94 congestion zone and an aggressive push toward triple digits.

Evercore ISI trimmed its target from $120 to $112, but kept an Outperform on Abbott Laboratories and flagged healthy procedure volumes and capital spending in MedTech, life sciences tools, and diagnostics ahead of Q2. Translation for traders: analysts are fine‑tuning valuation assumptions, not bailing on the story.

At the product level, the ALZpath deal is a big tell. ABT is licensing ALZpath’s pTau217 antibody to build a blood-based Alzheimer’s test on its Alinity ci-series analyzers. That takes a complex, expensive diagnostic pathway and aims to bring it into routine lab testing. If Abbott Laboratories executes, diagnostics could get a new high-margin growth leg that justifies those lofty price targets.

Meanwhile, policy tailwinds are forming. CMS is proposing an expansion of TAVR coverage, and ABT, as a structural heart and cardiovascular device player, is expected to see some benefit; the stock already traded slightly higher on that update. Reimbursement changes rarely make flashy headlines, but they quietly push procedure volumes and revenue higher over time.

Conclusion

For all the bullish noise, ABT still carries baggage, and traders ignore it at their own risk. The baby formula saga is not ancient history. The U.S. Department of Justice spent years on Abbott Laboratories’ Sturgis plant after potentially deadly bacteria was linked to infant deaths. In the end, DOJ dropped the criminal probe and moved toward a civil False Claims Act settlement aimed at recovering federal nutrition-program funds.

From a trading standpoint, that’s a huge shift. Criminal risk is off the table, but civil payouts and reputational drag remain. You can already see the market’s mixed read: ABT shares dipped about 1.3% on one DOJ headline even though no charges were filed. That’s classic “sell first, model details later” behavior, and it’s exactly where strict risk management matters most. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” For anyone sizing up ABT around headline risk, that mindset can be the difference between a controlled loss and a blown‑up account.

Abbott Laboratories is working to repair that side of the story. The Similac “Love Without Measure” campaign targets Gen Z and young millennial parents with more authentic, judgment‑free messaging, leaning on influencers and experts across social platforms. That’s a slow rebuild, not a one‑day catalyst, but it matters for sentiment.

The next hard catalyst for ABT is Q2 2026 earnings on 2026/07/16, with a webcast call scheduled. That’s where the Street’s 6%-8% sales growth and double-digit earnings growth narrative gets confirmed or challenged. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, only about catalysts and price action — learn to react, not predict.” With multiple bullish targets, an emerging Alzheimer’s diagnostic, and the DOJ cloud thinning, ABT is setting up as a name where disciplined traders can study the chart, respect key levels, and let the next catalyst do the talking.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!